Early diagnosis and swift treatment are critical to changing the lung cancer landscape. Our focus on clinical needs across the lung cancer continuum of care helps patients and providers confidently navigate the diagnostic pathway and optimal treatment decisions.
Nodify Lung® testing consists of two blood-based proteomic tests, the Nodify CDT® and Nodify XL2® tests, designed to help providers quickly and confidently decipher the risk of malignancy of a lung nodule.
Biodesix IQLung™ Treatment Guidance testing consists of the GeneStrat® targeted test, the GeneStrat NGS™ genomic test and the VeriStrat® proteomic test for a broader view of each patient's disease state, with average results ready in 72 hours or less.* IQLung testing empowers care teams with a testing strategy for any stage of non-small cell lung cancer (NSCLC) and delivers timely biological insights to help expedite personalized treatment decisions.
Learn more about our efforts to expand the clinical understanding of our current tests and clinical studies exploring new and ongoing diagnostic challenges.
Our in-house Customer Care experts are only a click away
Explore our library of publications, abstracts, videos, and more
*72 Hours represents the average turnaround time for testing, individual test turnaround times may vary.
1 Springmeyer et al. ATS Annual Meeting, May 14-19, 2021; San Diego, CA